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A potential target enzyme for trypanocidal drugs revealed by the
crystal structure of NAD-dependent glycerol-3-phosphate
dehydrogenase from Leishmania mexicana
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and Wim GJ Hol1,3*
Background: NAD-dependent glycerol-3-phosphate dehydrogenase (GPDH)
catalyzes the interconversion of dihydroxyacetone phosphate and L-glycerol-3-
phosphate. Although the enzyme has been characterized and cloned from a
number of sources, until now no three-dimensional structure has been
determined for this enzyme. Although the utility of this enzyme as a drug target
against Leishmania mexicana is yet to be established, the critical role played by
GPDH in the long slender bloodstream form of the related kinetoplastid
Trypanosoma brucei makes it a viable drug target against sleeping sickness.
Results: The 1.75 Å crystal structure of apo GPDH from L. mexicana was
determined by multiwavelength anomalous diffraction (MAD) techniques, and
used to solve the 2.8 Å holo structure in complex with NADH. Each 39 kDa
subunit of the dimeric enzyme contains a 189-residue N-terminal NAD-binding
domain and a 156-residue C-terminal substrate-binding domain. Significant
parts of both domains share structural similarity with plant acetohydroxyacid
isomeroreductase. The discovery of extra, fatty-acid like, density buried inside
the C-terminal domain indicates a possible post-translational modification with
an associated biological function.
Conclusions: The crystal structure of GPDH from L. mexicana is the first
structure of this enzyme from any source and, in view of the sequence identity
of 63%, serves as a valid model for the T. brucei enzyme. The differences
between the human and trypanosomal enzymes are extensive, with only 29%
sequence identity between the parasite and host enzyme, and support the
feasibility of exploiting the NADH-binding site to develop selective inhibitors
against trypanosomal GPDH. The structure also offers a plausible explanation
for the observed inhibition of the T. brucei enzyme by melarsen oxide, the active
form of the trypanocidal drugs melarsoprol and cymelarsan.
Introduction
Trypanosomatids are the cause of severe diseases in both
humans and livestock, causing considerable suffering espe-
cially in developing countries [1,2]. Several Leishmania
species are responsible for a variety of debilitating diseases,
collectively called leishmaniases, throughout the tropics and
subtropics, whereas two closely related trypanosomatids are
the causative agents of two other major global diseases. Try-
panosoma brucei gambiense and T. brucei rhodesiense cause
sleeping sickness in Africa and T. cruzi is responsible for
Chagas’ disease in Latin America. The health problems
caused by these protozoa are currently reaching disastrous
proportions with the resurgence of sleeping sickness across
central Africa [3,4]. There has also been an increase in the
frequency of HIV–Leishmania co-infections in southern
Europe [5]. The situation is further compounded by the
fact that organisms related to trypanosomatids that are not 
normally infectious to humans (e.g., herpetomonads and
leptomonads) are emerging in immunosuppressed patients
[6]. Despite the grave seriousness of the situation, the drugs
in use are outmoded and grossly inadequate. For example,
melarsoprol, the only drug against late stage T. brucei rhode-
siense infections, has such toxic side-effects that 5–10% of
the patients treated die due to reactive encephalopathy [7].
There is, therefore, an urgent need for better drugs, espe-
cially as the effectiveness of the few available drugs is being
eroded by increasing resistance [8].
Many biochemical aspects of the different life stages of
these parasites have been studied in detail and several
possible targets have been suggested for antitrypanosomal
chemotherapy [7,9]. One aspect of special relevance is
that the parasites are uniquely adapted to their complex
lifestyle in both a vertebrate host and an insect vector, and
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their energy metabolism changes depending on the avail-
ability of nutrients [10]. The bloodstream form of T. brucei
is totally dependent on glycolysis for energy generation,
and the first seven glycolytic enzymes are sequestered in a
specialized organelle called the glycosome [11], where gly-
colysis proceeds at a feverish pace [12,13]. Computer
modeling of the glycolytic flux supports the feasibility of
inhibiting the glycolytic enzymes and thereby blocking
glycolysis [14]. This Achilles heel is being exploited in our
laboratories by targeting a number of these glycosomal
glycolytic enzymes from both L. mexicana and T. brucei for
structure-based drug design [11,15–18].
NAD-dependent glycerol-3-phosphate dehydrogenase
(GPDH; EC 1.1.1.8) catalyzes the interconversion of dihy-
droxyacetone phosphate (DHAP) and L-glycerol-3-phos-
phate (G3P) using NAD as a cofactor. In the bloodstream
form of T. brucei, GPDH is especially important as it is
directly responsible for maintaining the NAD/NADH
balance in the glycosome by the reoxidation of the NADH
produced by glyceraldehyde-3-phosphate dehydrogenase
during glycolysis. The G3P generated is then transported
across the glycosomal membrane and reoxidized via the
G3P:DHAP shuttle that functions in conjunction with a
mitochondrial glycerol-3-phosphate oxidase [11]. Blocking
GPDH activity would seriously jeopardize ATP generation
by the trypanosome. The inhibition of GPDH would, in
addition, lead to the accumulation of DHAP in the glyco-
some. This would be very harmful to the trypanosome as
DHAP is spontaneously converted to methylglyoxylate, a
toxic compound that reacts aspecifically with proteins
[19,20]. In contrast to the vital role of GPDH in T. brucei, the
importance of this enzyme in L. mexicana and its value as a
drug target are yet to be evaluated, because in Leishmania
species glycolysis is less important for the energy supply and
glycolytically produced NADH is thought to be reoxidized
mainly via a glycosomal malate dehydrogenase [11,21,22].
Glycosomal GPDH from L. mexicana (LmGPDH) the main
subject of the present paper, is a polypeptide of 366 amino
acids that forms a homodimer of 78 kDa [21]. Like many of
the other glycolytic glycosomal enzymes, LmGPDH has a
very high isoelectric point of 9.5. GDPH from T. brucei is a
polypeptide of 354 amino acids, forms a dimer of 76 kDa
[21] and shares 63% sequence identity with the L. mexicana
enzyme. In both organisms the enzyme is expressed in the
cytosol and then targeted to the glycosome with the aid of a
type 1 C-terminal tripeptide peroxisomal targeting signal,
or PTS1 [13]. This tripeptide has the sequence SKL (in
single-letter amino acid code) in LmGPDH and SKM in
the T. brucei homolog. Here we present the crystal structure
of LmGPDH, both in its apo form and as a holo enzyme in
complex with NADH. To the best of our knowledge, this is
the first report of the crystal structure of this enzyme from
any source. The two-domain GPDH subunit shares signifi-
cant structural similarity with plant acetohydroxyacid 
isomeroreductase. Another surprise of the structure deter-
mination was the discovery of extra fatty-acid-like density
buried inside the C-terminal domain.
Results and discussion
Description of the overall structure
The crystal structure of LmGPDH at 1.75 Å resolution has
been refined to an R factor of 19.5%, with 93.3% of the
residues in the most favorable region of the Ramachandran
map [23]. The remaining 6.7% of the residues are in the
additional allowed regions, and there are no residues in the
generously allowed or disallowed regions. The asymmetric
unit contains a monomer composed of two domains
(Figures 1,2), as observed in other NAD(P)-dependent
dehydrogenases. The N-terminal NAD-binding domain
(residues 9–197) contains a canonical six-stranded parallel
β sheet [24] with helices on either side. In LmGPDH these
six strands are part of a larger eight-stranded β sheet with an
extra pair of strands running antiparallel to the six-stranded
Rossmann fold. The first β-α-β unit (Figures 1b,2) contains
the highly conserved GxGxxG NAD-binding motif [25]
that is present in all NAD-dependent GPDHs studied so
far [26]. The C-terminal substrate-binding and catalytic
domain (residues 200–357) is exclusively α-helical. This
domain contains a total of eight helices, which comprise
64.6% of the chain of this domain, and one particularly long
helix (helix 9; Figure 1b) consisting of residues 200–222.
The two domains are linked by a single three-residue loop.
The biological dimer is generated by crystallographic
twofold symmetry. Residues 343–357 of the C terminus of
each monomer wrap around the other monomer of the bio-
logical dimer and the residues of the two C termini
approach each other to within 10 Å (Figure 2). Although
the density for most of the structure was well defined
(Figure 3), the last nine residues (358–366) of the C termi-
nus, containing the PTS1 glycosomal targeting signal SKL,
are missing in density, as are the initial eight residues and
five residues of loop 293–297 in the C-terminal domain.
LmGPDH has a large dimer interaction surface, burying
1200 Å2 and 1924 Å2 out of 7888 Å2 and 7472 Å2 accessible
surface area on the N- and C-terminal domains, respec-
tively. The subunit–subunit interface is 70% nonpolar, but
is also stabilized by a number of hydrogen bonds and inter-
actions between sidechains of opposite charge. Although
the majority of the dimer contacts come from the C-termi-
nal α-helical domain, residues 156 to 166 of the N-terminal
domain contribute some important specific interactions. In
particular, the mainchain amino group of Phe156 is
involved in an intermonomer hydrogen bond with the
sidechain of Asn228. Asn228 is conserved among 23 of the
24 known GPDH sequences (the only exception being
GPDH from Helicobacter pylori, where this residue is a
serine). Also Glu159, which is totally conserved among the
24 known GPDH sequences, is involved in intermonomer
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hydrogen bonds to mainchain amino groups of Leu227 and
Asn228. The large dimer interface and the highly con-
served nature of the interface residues Gln159 and Asn228
suggest that the LmGPDH structure represents the general
dimeric picture of this enzyme across species.
The NAD-binding site 
The holo structure of LmGPDH in complex with NADH
was determined from crystals grown in the presence of
15 mM NADH. Crystals grown in the presence of NAD+
under similar conditions did not contain the cofactor, pre-
sumably because the Km for NAD+ is 420 µM as opposed
to 24 µM for NADH. The structures of apo and holo
LmGPDH are very similar to each other with 346 Cα
atoms superposing with a root mean square deviation
(rmsd) of 0.4 Å. The binding mode of NADH to
LmGPDH was clearly visible in the 2.8 Å holo enzyme
electron-density map (Figure 4a). The interactions of the
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Figure 1
The tertiary and secondary structure of
L. mexicana GPDH. (a) Stereoview Cα trace
of one monomer of holo LmGPDH. The bound
cofactor NAD is depicted in bold as a stick
model. The initial eight residues and last nine
residues are missing in density, as are the
residues in the loop 293–297, which is
depicted by dotted lines. This figure was
made with the program Molscript [50].
(b) Amino acid sequence alignment of GPDH
from L. mexicana, T. brucei and Homo
sapiens (SWISS-PROT accession numbers
P90551, P90593 and P21695, respectively).
The NAD-binding GxGxxG sequence motif is
colored green, putative active-site residues
are shown in blue, residues implicated in
interactions with the trypanocidal drug
cymelarsan in T. brucei GPDH (and the
equivalent residues in LmGPDH) are in red,
and the C-terminal PTS1 glycosomal targeting
signal is colored gold. Shaded in salmon is
the region of the sequence that could not be
aligned with confidence, due to the very low
sequence similarity between the human and
the two trypanosomatid sequences; the
corresponding residues (Asn24 to Lys47) of
the human sequence have been italicized.
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enzyme with the cofactor are depicted in Figure 4b. An
unusual feature of the NAD-binding site is the absence of
an acidic residue at the end of the second β strand of the
β-α-β motif. It is characteristic of NAD-binding dehydro-
genases (as opposed to NADP-binding dehydrogenases)
that there is an aspartate or a glutamate residue at this
position interacting with the 2′-hydroxyl group of the
adenosine ribose [25,26], although exceptions to this
pattern have been observed before [27]. In LmGPDH
(Figures 4a,b), which is an NAD-dependent enzyme, this
position is occupied by a histidine residue (His45). Com-
pared to other dehydrogenases, the mainchain of His45 is
moved away from the NAD with the nearest atom, the
imidazole Cγ, being at a distance of 4.7 Å from the
2′-hydroxyl. Instead of the usual acidic residue hydrogen
bonding to the 2′-hydroxyl of the adenosine sugar, in the
LmGPDH structure this hydroxyl hydrogen bonds to a
water molecule, which in turn interacts with the main-
chain amino group of Met46. The 3′-hydroxyl group is sta-
bilized by a hydrogen bond to Ser23. The adenine ring
packs against Phe97 and is shielded from solvent by
Met46, while the adenosine sugar sits snugly against Ile93
and Pro94. At the other end of NADH, the nicotinamide
makes hydrophobic contacts with Phe26, whereas the
nicotinamide ribose packs against Thr124 with its
3′-hydroxyl making a hydrogen bond to the mainchain
amino group of Lys125. The 2′-hydroxyl of the nicoti-
namide sugar is stabilized by a hydrogen bond to the
sidechain carboxylate of Glu300, provided by helix α14.
The rotational isomer of the glycosyl bond around the
nicotinamide is syn, with the hydride being added to the
proS position of the pyridine ring based on the putative
substrate-binding site (discussed below).
The active site
The structure of LmGPDH in complex with NADH permits
us to delineate the putative active site. Residues Lys125,
Lys210, Asp263 and Thr267 are located in the vicinity of the
nicotinamide ring (Figure 5), suggesting that they might be
involved in substrate binding or catalysis. This idea is sup-
ported by the fact that Lys125, Lys210 and Glu263 are
absolutely conserved in the 24 available sequences, whereas
Thr267 is conserved in 23 sequences and is a serine residue
in Saccharomyces pombe A [28]. The basic sidechains of the
two lysine residues create a phosphate-binding site (as
determined using the program GRID [29]) that presumably
accommodates the phosphate of the substrate G3P during
catalysis. The carboxylate oxygens of Asp263 are 6.3 Å from
C4 of the nicotinamide and the hydroxyl oxygen of Thr267
is 7.2 Å from C4. It is likely that both Asp263 and Thr267
move towards the nicotinamide during catalysis, as the
domains may come closer upon substrate binding. Such
domain motions during substrate and cofactor binding have
been observed in a number of dehydrogenases including
glutamate dehydrogenase [30,31], liver alcohol dehydroge-
nase [32] and glyceraldehyde-3-phosphate dehydrogenase
[33]. Other residues relatively close to the nicotinamide that
could possibly have a role in substrate binding are Asn211,
Arg274 and Asn275, of which the latter two are totally con-
served, whereas Asn211 is conserved in 23 known sequences
and is an aspartate in rabbit GPDH [34]. The sidechain
amide of Asn211 is 7.8 Å from the nicotinamide C4 and the
amide of Asn275 is 9.6 Å from C4 in the holo complex, while
the sidechain of Arg274 appears flexible. Although the eluci-
dation of the reaction mechanism clearly requires more
structural and biochemical investigation, it is likely that
Asp263 and Thr267 are critical catalytic residues as these are
closest to the C4 of the nicotinamide.
Structural similarities and evolutionary links
Although the similarity of the N-terminal domain of
GPDH to other NAD-binding enzymes was anticipated, it
was surprising to discover, using the program DALI [35],
that the α-helical C-terminal domain has a partial but strik-
ing similarity to the bifunctional enzyme acetohydroxyacid
isomeroreductase (EC 1.1.1.86) from plants. The Spinacia
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Figure 2
Tertiary structure of dimeric LmGPDH with the reference monomer
shown in brighter colors than the other. Within each monomer the
N-terminal NAD-binding domain is colored green and the C-terminal
substrate-binding domain is violet. Highlighted in cyan is the
nucleotide-binding β-α-β structural motif; bound NAD is depicted as a
ball-and-stick model in green. The aliphatic molecule near Cys345 is
shown in gold. Putative active-site residues are highlighted in blue and
residues corresponding to those reported to interact with the
trypanocidal drug cymelarsan in T. brucei are in red [20]. The last
residues (335–357) visible in the electron-density map, which precede
the C-terminal tail with residues 358–366 containing the PTS1 SKL
glycosomal import signal, are depicted in bright yellow. This figure was
made with Molscript [50] and Raster3D [51].
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oleracea isomeroreductase [36] is a dimer, but has entirely
different subunit–subunit interactions to those of
LmGPDH (data not shown). However, the similarity in
structure of the individual subunits of these two enzymes
is especially interesting considering that acetohydroxyacid
isomeroreductase catalyzes an alkyl migration followed by
a reduction, uses NADPH as a cofactor, and needs a biva-
lent metal cation for activity, whereas, in contrast,
LmGPDH does not migrate an alkyl function, uses NAD as
cofactor, and does not need a metal cation for activity.
The structural similarity encompasses both the topology as
well as the positioning of the secondary structure elements
in both the canonical NAD(P)-binding N-terminal domain
as well as parts of the substrate-binding C-terminal domain
(Figure 6). The 158 equivalent Cα atoms in the two struc-
tures superpose with an rmsd of 3.2 Å despite a sequence
identity of only 13.3%. The cofactor-binding domains have
103 residues in common with a sequence identity of 16.5%
and an rmsd of 2.9 Å. In the C-terminal domains, 55
residues superimpose with an rmsd of 3.4 Å (sequence iden-
tity as low as 7.3%). The common feature in the C-terminal
domains of both enzymes is a three-helix bundle (Figure 6),
two helices of which provide key residues to the active site.
In the isomeroreductase the helices comprising residues
Leu308–Arg320 and Leu324–Glu340 contribute Asp315
and Glu319 to chelate the Mg2+ ions at the active site [36],
whereas in LmGPDH the structurally equivalent long helix
(Thr200–Gly222) contributes Lys210 to the putative active
site. In addition, the consecutive helices Tyr486–Ser493
and Ile495–Asp499 of the isomeroreductase contribute
Glu492 and Glu496 to the putative active site, and in
LmGPDH the equivalent helix (Leu261–Cys268) con-
tributes Asp263 and Thr267 to the active site. Although the
two enzymes bind different substrates, the specific catalytic
residues are in a similar spatial juxtaposition. After superpo-
sition of the 158 equivalent Cα atoms of the two enzymes,
the Cα atom of Lys210 in LmGPDH is 3.1 Å from the Cα
atom of Glu319 in the isomeroreductase, the Cα atom of
Asp263 of LmGPDH is 3.0 Å from Glu492 of the isomerore-
ductase, and the Cα atom of Thr267 of LmGPDH is 4.9 Å
from the Cα atom of Glu496 of the isomeroreductase.
Similar distances between catalytically equivalent residues
in distantly related proteins have been reported elsewhere
(see e.g. [37]). This extensive similarity of LmGPDH to a
functionally distantly related plant enzyme raises interesting
questions regarding its evolutionary history.
One possible explanation for the structural similarity
between GPDH and the isomeroreductase is that they are
descendants of the same bifunctional protein and have
widely diverged during the course of evolution, while
maintaining essentially the same relative orientation of the
three common C-terminal helices with respect to the
N-terminal nucleotide-binding domain. Another possibil-
ity is that the C-terminal domains of these two enzymes
evolved independently in different kingdoms and were
fused to one of the many genes coding for nucleotide-
binding proteins. The similarity in the orientation of the
C-terminal helices with respect to the N-terminal domain,
would in this scenario, either be fortuitous or imposed by
the constraint of placing critical residues in the active site
located in-between the two domains.
Post-translational modification of trypanosomatid GPDHs
A most surprising discovery of our structure determina-
tion was the observation of extra electron density in
the unbiased experimental map at 1.75 Å resolution
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Figure 3
Representative section of the experimental
electron-density map after density
modification of apo LmGPDH at 1.75 Å. The
highly conserved putative active-site residues
Asp263 and Thr267 are labeled. The figure
was made with Bobscript [52].
Thr267
Asp263
Thr267
Asp263
Structure
(Figure 7). The density is compatible with an extended
aliphatic molecule with a length of approximately 16
carbon atoms. The molecule is located in a well defined,
entirely hydrophobic pocket created by sidechains from
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Figure 4
Cofactor binding by GPDH. (a) Simulated
annealing omit map [53] of the
LmGPDH–NADH holo complex, contoured at
2.8σ, superposed on the refined model of
NADH. Residues that differ between the
human and the two trypanosomatid enzymes
(L. mexicana and T. brucei) are in red;
conserved residues are in green. Also
indicated in red are the water molecule that
forms a hydrogen bond to the 2′ oxygen of the
adenosine ribose in LmGPDH, instead of the
usual acidic residue that is found in most
NAD-dependent dehydrogenases [25,26],
and the region around the β2 loop that shows
considerable sequence difference between
human and trypanosomatid enzymes (salmon-
shaded in Figure 1b). (b) A LIGPLOT [54]
representation of the cofactor-binding site,
showing the interactions between NADH and
LmGPDH. Residues that are conserved
between the human and two trypanosomatid
enzymes are labeled in green; those that are
different are labeled in red. Atoms are shown
in standard colors.
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Figure 5
Close-up stereoview of the active site of the
LmGPDH–NADH holo complex. Residues from
the N-terminal NAD-binding domain are shown
in green, residues from the C-terminal
substrate-binding domain in violet, and the
three-residue linker between the two domains
is in red. Active-site residues Lys125, Lys210
and Asp263 are totally conserved among the
24 known GPDH sequences, whereas Thr267
is a serine in Saccharomyces pombe A and a
threonine in the other 23 sequences.
Lys125Asp263
Lys210
Asn211
Thr267
Asn275
Arg274
Asp263Lys125
Lys210
Asn211
Thr267
Asn275
Arg274
Structure
the C-terminal domain of one monomer and the N-termi-
nal domain of the other monomer of the biological dimer
(Figure 7). One end of the density approaches Cys345.
Although the density did not indicate a covalent linkage
to this cysteine in the recombinant enzyme produced in
Escherichia coli, it is plausible that the native enzyme in
the trypanosome is post-translationally modified by a
covalent linkage to this cysteine which is conserved
among the L. mexicana and T. brucei GPDH sequences.
Covalent modification of cysteine residues has been
known to occur in T. brucei, with reversible thiomyristoyla-
tion being implicated in the regulation of the integral
membrane protein glycosylphosphatidylinositol-specific
Research Article  NAD-dependent glycerol-3-phosphate dehydrogenase Suresh et al. 547
Figure 6
Structurally conserved regions between
LmGPDH and Spinacia oleracea
acetohydroxyacid isomeroreductase. In addition
to the similarity of the N-terminal NAD-binding
region (in green) of LmGPDH to the
isomeroreductase (in red), a three-helix bundle
(in violet) in the C-terminal substrate-binding
domain of LmGPDH is structurally conserved in
the isomeroreductase (in red). Specifically, helix
9 (Thr200–Gly222) of LmGPDH is structurally
equivalent to the helices Leu308–Arg320 and
Leu324–Glu340 of the isomeroreductase, helix
11 (Leu261–Cys268) of LmGPDH is
equivalent to the consecutive helices
Thr486–Ser493 and Ile495–Asp499 of the
isomeroreductase, and helix 10
(Leu227–Ala247) of GPDH is equivalent to
Pro462–Lys481 of the isomeroreductase. The
bound cofactors are depicted as stick models:
NAD in LmGPDH is in green, and NADPH in
the isomeroreductase is in red. Also indicated
are the residues from the critical three-helical
bundle of the C-terminal domain that are
believed to contribute to the active site. In
performing the superposition, segments 16–35,
40–46, 52–58, 74–108, 117–124, 147–163,
165–172, 199–213, 215–224, 228–244 and
258–269 of LmGPDH were superposed onto
segments 126–145, 156–162, 168–174,
182–217, 218–225, 245–261, 272–279,
307–321, 325–334, 466–482 and 487–498
of the isomeroreductase.
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Figure 7
Density-modified MAD map, prior to model
building, showing the extra density in the
hydrophobic pocket of recombinant apo
LmGPDH. This density was subsequently
modeled as a linear aliphatic molecule.
Secondary structure elements from the
C-terminal domain are colored violet and
those from the N-terminal domain of the
symmetry-related monomer are colored dark
green. The cysteine residue (Cys345) that is
believed to be post-translationally modified in
the native enzyme is labeled, as is the helix
(the lid helix) that is postulated to move during
glycosomal import, exposing the aliphatic
modification and facilitating glycosomal
membrane association.
Cys345 Cys345
Lid helix
α16     
Lid helix
α16     
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phospholipase C (GPI-PLC) [38]. More recently it has
been demonstrated that GPI-PLC introduced as a reporter
protein in Leishmania major also undergoes S-myristoyla-
tion [39]. In Trypanosoma cruzi it has been observed that
palmitoylation of a cysteine residue from a flagellar
calcium-binding protein, coupled with myristoylation of
the N-terminal glycine, is necessary for the association of
the protein to the flagellar membrane [40]. Hence, the
extra density near Cys345 suggests the occurrence of a
post-translational modification of this cysteine in try-
panosomatids, even though the electron density does not
indicate a covalent link between the extra density and this
cysteine in the recombinant enzyme.
A possible connection between recognition of the PTS1
signal and a function of the putative covalent modification
of Cys345 might exist. Although the last nine residues
(358–366) of LmGPDH, including the PTS1 import signal,
are not visible in the density, the preceding residues are
well ordered. Of these, residues 343 to 357 wrap around
the second monomer of the dimer (Figure 2), while helix
α16, comprising the preceding residues 335–342, is
involved in forming the hydrophobic pocket containing
the extra fatty acid density (Figure 7). Inspection of the
structure suggests that movement of the ‘lid helix’ α16
would open up the hydrophobic pocket and expose the
covalently linked aliphatic molecule, which could then
associate with the glycosomal membrane. Such an opening
of the pocket is postulated to take place during the mem-
brane translocation process and hence after the interaction
of the C-terminal PTS1 tripeptide with its Pex5 receptor
(Figure 8). This sequence of events would permit this try-
panosomal enzyme to be soluble prior to transport into the
glycosome, and once imported into the glycosome to
become associated with the inner leaflet of the glycosomal
membrane. Such a membrane association of this enzyme
548 Structure 2000, Vol 8 No 5
Figure 8
Hypothetical scheme for the import of L.
mexicana and other trypanosomatid GPDHs
into the glycosome, mediated by Pex5, and
subsequent membrane association through an
aliphatic modification of a cysteine residue. It
is hypothesized (see text) that prior to
targeting to the glycosome, the putative
aliphatic modification is enclosed in a
hydrophobic pocket within the soluble protein,
and once imported into the glycosome
movement of a helix that caps the
hydrophobic pocket would open up the
pocket, exposing the aliphatic molecule and
permitting membrane association. 
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would be consistent with the fact that the product of the
reaction it catalyzes, namely G3P, has to be transported
across the glycosomal membrane to be reoxidized by the
mitochondrial G3P oxidase. Membrane association of try-
panosomatid GPDH would also be in accordance with the
observation of Stebeck et al. [41], that during the purifica-
tion of T. brucei GPDH from African trypanosomes, the
enzyme is present in the glycosomal membrane fraction. It
is possible that GPDH could be somehow associated with
the G3P transporter (Figure 8). Clearly, further experi-
mental studies are needed to confirm this hypothesis.
Drug design
The vital role played by GPDH in the glycosome of the
bloodstream form of T. brucei, coupled with the low degree
of sequence conservation between the trypanosomal and
the human enzyme, makes it a promising target for drug
design. Computer modeling of the glycolytic flux, based on
experimentally determined kinetic parameters of the try-
panosomal enzymes, corroborates the feasibility of blocking
glycolysis in T. brucei by inhibiting GPDH [14]. While
GPDH may or may not be a good drug target in Leishmania
species, the enzyme from L. mexicana presented here pro-
vides us with an excellent model for the trypanosomal
enzyme. The fact that the active sites of enzymes are
usually extremely well conserved, makes the development
of inhibitors with high affinity for the active site of the para-
site enzyme, and with low affinity for the active site of the
homologous host enzyme, often an intractable problem. It is
possible to circumvent this obstacle when the enzyme uti-
lizes a large cofactor like NAD, as usually there are substan-
tial differences between the parasite and host enzymes in
regions that bind parts of the cofactor that are distant from
the active site. Selective inhibitors can then be designed
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Figure 9
Drug target areas in trypanosomatid GPDH.
(a) View of the hydrophobic pocket near the
adenosine-binding site that can potentially be
exploited for structure-based drug design.
Labeled in red are residues that differ between
the human and T. brucei sequences; residues
that are identical are labeled in green. This
figure was made with GRASP [55] and
Molscript [50]. (b) Residues in LmGPDH that
correspond to those implicated in interactions
with the trypanocidal drug cymelarsan in T.
brucei. Cys123 and Cys203 are conserved
between L. mexicana and T. brucei, whereas
Ser169 is a cysteine residue that is unique to
T. brucei. The Oγ atom of Ser169 is 4.0 Å
from the Sγ atom of Cys203.
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that bind these regions of the cofactor-binding site on the
parasite enzyme with higher affinity than those of the host
enzyme. This approach has been successful in the design
and synthesis of selective inhibitors of trypanosomatid glyc-
eraldehyde-3-phosphate dehydrogenase [18].
The sequences of GPDH from T. brucei and L. mexicana are
63% identical and there are no insertions or deletions. The
two trypanosomatid sequences differ considerably from the
human enzyme, with only 28.5% and 29.8% identity, respec-
tively (Figure 1b). As can be seen from Figure 9a, the differ-
ences are significant especially in the binding site of the
adenosine portion of NAD. In fact, the residues in the loop
after the second β strand of the canonical β-α-β motif (after
His45) are so different (Figure 1b) that it is not possible to
be confident about the alignment. As mentioned previously,
in most NAD-binding dehydrogenases the residue equiva-
lent to His45 of LmGPDH is occupied by an acidic residue
that makes a hydrogen bond to the 2′ oxygen of the adeno-
sine sugar. In the human enzyme there is an insertion in this
region (Figure 1b), indicating substantial differences in the
tertiary structure. We hope to exploit these differences in
the adenosine-binding region to develop adenine analogs as
selective inhibitors against the parasite enzyme.
It is also anticipated that the affinity of these analogs could
be improved by exploiting the hydrophobic cavity below the
adenine ring formed by Ile93, Trp44 and Met46 (Figure 9a).
Filling this pocket by attaching hydrophobic groups to the
C2 position of the adenine would be likely to create favor-
able hydrophobic interactions between the ligand and target
proteins and result in tight-binding inhibitors. Alternatively,
adding substituents to the 2′ position of the adenosine sugar,
which would displace the hydrogen bonded water molecule
and interact with hydrophobic groups of nearby residues,
might increase the affinity for the parasite enzyme but
decrease the affinity for the human homolog.
The role of GPDH dehydrogenase as a possible trypanoso-
mal drug target is underscored by the observed inhibition of
the enzyme by cymelarsan (an analog of melarsoprol),
suramin, pentamidine and berenil [20,42,43], drugs in use
against African trypanosomiasis. The inhibition by
cymelarsan is especially interesting as this arsenical, which
is the only available treatment against late stage T. brucei
rhodesiense infections, forms covalent links with T. brucei
GPDH [20]. Of the two cysteine residues implicated in
interactions with this compound, Cys123 in LmGPDH
(Cys116 in T. brucei) is close to the NAD-binding site, with
its Sγ atom 7.7 Å from C6 of the nicotinamide (Figure 9b).
Although the Sγ atom of Cys123 points towards the
hydrophobic interior of the protein in both the native and
holo structures, a change in the sidechain χ1 dihedral angle
could expose the Sγ atom to the solvent. The other cys-
teine, Cys203 in L. mexicana (Cys196 in T. brucei), is located
near the active site with its Sγ atom positioned 8.8 Å and
8.9 Å from the nearest sidechain atoms of the active-site
residues Lys125 and Asp263, respectively. This cysteine
occurs at the interface between the N- and C-terminal
domains and is, in the present structures, not accessible to
solvent. The Sγ atoms of Cys123 and Cys203 are 11.5 Å
apart in the LmGPDH structure. Interestingly, a third cys-
teine (Cys162) occurs in the T. brucei enzyme, which is a
serine (Ser169) in LmGPDH. This residue also occurs at the
domain interface near the active site with its Oγ atom 4.0 Å
from the Sγ of Cys203 (Cys196 in T. brucei). This suggests
the possibility that an interdomain motion may open up the
interface and that subsequently a divalent interaction of
Cys162 and Cys196 with cymelarsan occurs in T. brucei.
This is consistent with the observation that cymelarsan
immobilized on a column binds T. brucei GPDH [20] but
does not bind LmGPDH (T Baltz, personal communica-
tion), presumably because the latter enzyme does not have
two cysteine residues in the active site sufficiently close
together. Although it might be difficult to alleviate the toxi-
city of this arsenical drug, and derivatives thereof, further
studies on its precise interaction with LmGPDH, and in
particular with the T. brucei enzyme, would be of value for
the development of novel inhibitors.
Biological implications
The crystal structure of NAD-dependent glycerol-3-
phosphate dehydrogenase (GPDH) from Leishmania
mexicana presented here is the first structure of the
enzyme from any source. The structure reveals that the
enzyme has the canonical two-domain NAD-dependent
dehydrogenase architecture, with an N-terminal NAD-
binding domain and a C-terminal substrate-binding
domain connected by a single short loop. The biological
molecule is a dimer with residues from both the N- and
C-terminal domains contributing to the extensive dimer
interface. The complex with NADH allows identifica-
tion of the residues involved in NAD binding and those
forming the putative active site. The structure also pro-
vides a plausible explanation for the observed inhibition
of the T. brucei enzyme by the trypanocidal drug
cymelarsan. The residues in the L. mexicana structure
corresponding to those implicated in interactions with
the drug in the T. brucei enzyme are near the active site
and cofactor-binding site.
A surprising observation was the extensive structural simi-
larity of L. mexicana GPDH to the enzyme acetohydroxy-
acid isomeroreductase from Spinacia oleracea. The
similarity extends not only to the N-terminal NAD-
binding domain, but also to the C-terminal substrate-
binding domain. Specifically, the C-terminal domains of
both structures contain a crucial three-helix bundle, two
helices of which contribute active-site residues. This unex-
pected similarity to a functionally distantly related plant
enzyme suggests several possible scenarios with respect to
the evolutionary relationship of these two proteins.
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An interesting finding of the structure elucidation was
the presence of extra electron density compatible with an
extended aliphatic molecule in a well defined, entirely
hydrophobic pocket with one end of the density close to
the Sγ atom of Cys345. This observation suggests a post-
translational modification of this cysteine in trypanoso-
matid GPDH, which may be of relevance for the
localization of the enzyme inside the glycosome.
Materials and methods
Preparation and purification of LmGPDH
LmGPDH overproducing E. coli were essentially grown and lysed as
previously described [21]. The cell lysate was clarified by centrifugation
at 10,000 g for 30 min and the supernatant with the soluble protein
was passed through a 0.45 µm filter. The high pI of the enzyme
enabled the purification of the crude lysate by a single pass over a
SPRINT 20HS cation exchange column. The enzyme was then concen-
trated to 3.5 mg/ml and buffer exchanged into 20 mM TEA pH 7.2,
4 mM NAD, 4 mM DTT, 1 mM EDTA and 0.2 mM PMSF.
Crystallization and data collection
A number of different crystal forms of LmGPDH were grown employing
the sitting drop vapor diffusion method with a variety of precipitants
including sodium formate, sodium citrate and PEG 5000 mme (mono
methyl ether). Crystals grown at room temperature by mixing 4 µl of the
protein solution with 2 µl of the reservoir solution composed of 0.9 M
sodium citrate were the most robust and were utilized for structure
solution. These crystals were transferred to a cryo-solution containing
0.9 M sodium citrate, 25 mM TEA pH 7.2, 4 mM NAD, 5 mM DTT,
0.2 mM EDTA and 15% v/v ethylene glycol, and frozen under a stream
of nitrogen prior to data collection. The single platinum derivative used
in the MAD phasing experiment was grown by equilibrating 3 µl of the
protein solution against 2 µl of the reservoir solution containing 0.6 mM
K2Pt(CN)6 and 0.95 M sodium citrate, and the crystal obtained was
frozen as described above. Despite the presence of 4 mM NAD in the
protein solution, the native crystal structure did not contain any density
for the dinucleotide. Crystals in complex with NADH were grown by
substituting 15 mM NADH for the NAD and setting up crystallization
experiments as before. The holo crystals were transferred to the above
mentioned cryo-solution that contained 15 mM NADH (instead of 4 mM
NAD) and frozen as before.
Structure determination
The native apo and holo data sets were collected at the Stanford
Synchrotron Radiation Laboratory (SSRL) beamline 7-1 and
processed with DENZO and SCALEPACK (Table 1). The platinum
MAD data set at four wavelengths was collected on SBC beamline
19-ID at the Advanced Photon Source (APS) in the Argonne National
Laboratory. After an Extended X-ray Absorption Fine Structure
(EXAFS) scan on a frozen crystal to determine the peak and inflection
point, a four-wavelength MAD experiment was conducted with a low
energy and a high energy reference. The MAD data set was essen-
tially complete with high redundancy to 2.5 Å, but the completeness
fell off rapidly between 2.5 and 2.0 Å. A single platinum site was
determined from difference Pattersons and its parameters refined
with SHARP [44], before locating two weaker sites from residual
Fouriers and including them in the phasing process. A 2.5 Å resolu-
tion map, calculated after solvent flipping with the SOLOMON option
in SHARP, was easily interpretable. This map was then used to
perform further density modification and phase extension to 1.75 Å
with the isomorphous native (apo) data set using the program WARP
[45]. The density at this stage was simply superb (Figure 3). The
model was built with the program O [46]. After initial refinement with
X-PLOR [47] the model was refined with TNT [48]. The holo crystals
were essentially isomorphous to the apo form and after initial rigid-
body positioning the structure was refined with CNS [49]. Refine-
ment statistics are provided in Table 1.
Accession numbers
The coordinates have been deposited in the PDB with accession
codes 1EVY and 1EVZ.
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